SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies. Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
Longwood Fund is a leading healthcare venture capital firm that founds, manages, and builds healthcare companies. Longwood’s mission is to identify technologies and to found companies that will advance new therapeutics that not only make a difference in the lives of patients worldwide, but also create significant value for investors. This is achieved by leveraging the management team’s history of successful healthcare company formation and operational leadership.
SV Life Sciences
SV Life Sciences is a leading international life sciences venture capital firm, and has been investing in life sciences companies since the early 1980s. The SVLS team manages approximately $1.9 billion of capital, and the firm employs a diversified strategy within life sciences in order to selectively capitalise on an expanding opportunity in biotech, medical devices and healthcare services.
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC is the venture capital subsidiary of Johnson & Johnson, and is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, healthcare trends, and strategic investment opportunities. They invest in companies with technologies that they believe have the potential to make significant impact on patient health.
Touchstone Innovations (formerly Imperial Innovations) are focused on commercialising the best in UK academic research, drawn from academic centres within the ‘golden triangle’ formed by Cambridge, Oxford and London. They have end-to-end capability, taking research at the earliest stage and working with it right through to commercialisation.
F-Prime Capital is the new, unified name for the venture capital funds of FMR LLC, the parent company of Fidelity Investments, and continue its 40-year history as an active global investor in life sciences, healthcare and technology. Over the past 15 years, the F-Prime Capital teams have invested in more than 89 companies in five countries across five funds. The teams have focused on innovative early stage companies addressing significant needs in the technology and life sciences sectors.